Articles published by Pheast Therapeutics

Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026

April 17, 2026

From Pheast Therapeutics

Via GlobeNewswire

Pheast Therapeutics Advances PHST001, an IgG4 Anti-CD24 Monoclonal Antibody, into Phase 1b Combination Cohorts

March 31, 2026

From Pheast Therapeutics

Via GlobeNewswire

Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001, a Novel Anti-CD24 Antibody, at AACR 2026

March 17, 2026

From Pheast Therapeutics

Via Business Wire

Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer

June 03, 2025

From Pheast Therapeutics

Via Business Wire

Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors

April 14, 2025

From Pheast Therapeutics

Via Business Wire

Pheast Appoints Dr. Raphaël Rousseau as Chief Medical Officer

February 18, 2025

From Pheast Therapeutics

Via Business Wire

Pheast Presents New Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor, at SITC 2024

November 07, 2024

From Pheast Therapeutics

Via Business Wire

Pheast Unveils First Preclinical Data for PHST001, an Anti-CD24 Macrophage Checkpoint Inhibitor

May 13, 2024

From Pheast Therapeutics

Via Business Wire

Pheast Appoints Jacopo Leonardi as Chief Executive Officer

January 05, 2023

From Pheast Therapeutics

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.